Editas Medicine, a clinical-stage genome editing company, has announced the appointment of Linda C. Burkly, Ph.D., as its Executive Vice President and Chief Scientific Officer. Dr. Burkly brings over 35 years of experience in biotechnology and will lead Editas’ drug discovery team and activities related to its pipeline of experimental medicines.
Editas Medicine aims to be a leader in programmable in vivo gene editing, and the addition of Dr. Burkly to the team will help realize this vision. She has a strong track record of inventing or contributing to multiple approved medicines and late-stage clinical candidates. With her deep scientific knowledge and translational abilities, Dr. Burkly will be an ideal leader for Editas’ drug discovery team and a valuable partner to the clinical organization.
Dr. Burkly expressed her enthusiasm for joining Editas and the opportunity to build their pipeline with a focus on gene editing medicines that differ significantly from the current standard of care for serious diseases. She is eager to work with the team of scientists at Editas to develop transformative treatments for patients and achieve success for all stakeholders.
Throughout her career, Dr. Burkly has made significant contributions to the foundations of approved medicines and late-stage clinical candidates. Her experience spans therapeutic areas such as immunological, neurological, and rare genetic disorders. Prior to joining Editas, she held various positions at Biogen over a span of 37 years, where she led neuroscience-focused research teams and played a vital role in inventing therapeutic compositions and discovering novel pathway biology.
Dr. Burkly holds a Ph.D. from Tufts University Graduate School of Biomedical Sciences and a B.S. from Fairfield University. She is recognized as an accomplished researcher and has collaborated on several innovative projects.
Editas Medicine is a clinical-stage genome editing company focused on translating the power and potential of CRISPR/Cas12a and Cas9 genome editing systems into a pipeline of treatments for serious diseases. The company aims to develop and commercialize transformative precision genomic medicines for various diseases. By leveraging its expertise in gene editing, Editas Medicine is at the forefront of advancing the field of medicine.
Editas Medicine’s appointment of Dr. Burkly as the Executive Vice President and Chief Scientific Officer signals a significant step forward in their mission to bring forth innovative gene editing therapies. With her extensive experience and leadership, Dr. Burkly will play a crucial role in driving the company’s drug discovery efforts and advancing their pipeline of experimental medicines.
